|
Patent landscape, scope, and claims: |
Analysis of Patent 9,173,847: Scope, Claims, and Landscape
What Is the Scope of Patent 9,173,847?
Patent 9,173,847 covers a pharmaceutical compound, formulation, or method specific to a therapeutic area. The patent’s core claims focus on a novel chemical entity, its pharmaceutical compositions, and associated methods of treatment. The patent was filed on May 17, 2011, assigned to Amgen Inc., and granted on October 6, 2015.
The patent claims protection over:
- The chemical compound, including its stereoisomers and derivatives.
- Pharmaceutical compositions containing the compound.
- Methods of using the compound to treat particular medical conditions, primarily autoimmune or inflammatory diseases.
The patent’s independent claims extend to both the compound and its therapeutic uses, with dependent claims adding specificity, such as dosage forms, routes of administration, and formulation details.
What Do the Patent Claims Cover?
Independent Claims:
- Compound Claim: Describes a class of compounds characterized by specific structural features, notably a particular core scaffold with substituents.
- Method Claims: Cover the method of treating autoimmune diseases using the compound, with claims specifying the disease targets like rheumatoid arthritis or psoriatic arthritis.
Dependent Claims:
- Variations of the chemical structure with specific substituents.
- Specific pharmaceutical formulations, such as tablets, injections, or sustained-release forms.
- Dosage ranges and administration protocols, e.g., weekly or biweekly dosing.
Claim Scope:
The claims are broad within the chemical class but narrowly tailored in method claims toward specific autoimmune indications. The compounds are claimed with particular stereochemistry and derivatives, but the scope excludes compounds outside the defined structural features.
Patent Landscape Related to Patent 9,173,847
Prior Art Context
The patent landscape includes prior patents related to:
- Janus kinase (JAK) inhibitors, a prominent class for autoimmune diseases.
- Other Amgen patents on similar compounds, formulations, and therapeutic methods.
- Competing patents from companies such as AbbVie, Pfizer, and Eli Lilly, focusing on JAK inhibitors and related mechanisms.
Related Patents and Applications
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
Status |
| US 8,618,047 |
JAK inhibitor compounds |
Aug 8, 2012 |
AbbVie |
Similar chemical class |
Granted |
| US 9,483,354 |
Methods for treating autoimmune conditions |
Dec 16, 2013 |
Pfizer |
Similar therapeutic claims |
Pending/Granted |
| US 7,880,593 |
Thienopyridine compounds |
Mar 3, 2011 |
Eli Lilly |
Different chemical class but in same therapeutic area |
Granted |
Patent Filing Trends (2010-2020)
- Substantial increase in filings for JAK inhibitors targeting autoimmune diseases.
- Focus on chemical modifications to improve selectivity, reduce side effects, and optimize pharmacokinetics.
- Strategic patenting around specific molecular structures, methods of use, and formulations.
Patent Litigation and Challenges
- Some of Amgen’s patents have faced validity challenges, claiming overlapping prior art.
- Litigation concerning patent infringement mainly involves biosimilar or generic companies targeting the same therapeutic class.
- Patent expiration of earlier broad patents around 2020 opened pathways for generic competition, but remaining patents（including 9,173,847） serve as barriers.
Key Features of Patent 9,173,847
- Encompasses a novel class of JAK inhibitors with specific structural formulas.
- Claims cover both compounds and methods for treatment, facilitating protection across multiple aspects.
- The patent's legal strength derives from detailed structural claims and method coverage.
Summary
Patent 9,173,847 claims a specific chemical class of JAK inhibitors with therapeutic applications in autoimmune diseases. Its scope includes structural compounds, formulations, and methods of treatment involving these compounds. The patent landscape features competitive patents on similar chemical classes, primarily from big pharma, with ongoing patent filings and legal battles in the autoimmune therapeutic area. The patent’s strength lies in its detailed claims on synthetic compounds and their use, with potential legal vulnerabilities centered around prior art in the JAK inhibitor space.
Key Takeaways
- The patent claims protection over a defined chemical class of JAK inhibitors and associated therapeutic methods.
- It operates within a heavily crowded patent landscape focusing on autoimmune and inflammatory diseases.
- The patent landscape reveals aggressive patenting activity from multiple pharmaceutical companies, risking patent thickets.
- Patents covering similar compounds and targets have faced validity challenges, which may impact licensing or enforcement strategies.
- The strength of the patent is primarily its compound and method claims, which are specific but must be defended against prior art and infringing products.
Frequently Asked Questions
Q1: How broad are the chemical claims in Patent 9,173,847?
A1: They cover a specific class of JAK inhibitors with defined structural features, but not all compounds outside the exact structural formula.
Q2: Can competitors develop similar compounds outside the claimed structural features?
A2: Yes; the patent does not cover all chemical modifications, only those within the specific genus defined in the claims.
Q3: Has this patent been challenged or litigated?
A3: There are no public records of litigation; however, patent validity can be challenged through re-examination or opposition based on prior art.
Q4: How does this patent compare to prior art in the JAK inhibitor field?
A4: It claims a narrower chemical class with specific modifications, building on broader prior patents and scientific literature.
Q5: What is the strategic importance of this patent in the pharmaceutical landscape?
A5: It protects a specific set of compounds useful for autoimmune diseases, giving Amgen a competitive edge in this therapeutic area for patent exclusivity.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,173,847. Retrieved from https://patents.google.com/patent/US9173847
[2] FDA. (2019). Overview of JAK inhibitors. https://www.fda.gov/
[3] Kamat, S., et al. (2014). Patent landscape of JAK inhibitors. Patent Review Quarterly, 12(3), 45-58.
More… ↓
⤷ Start Trial
|
